Literature DB >> 3816477

Secretin provocation in normal and duodenal ulcer subjects. Is the gastrin rise in Zollinger-Ellison syndrome paradoxic or exaggeration?

C E Brady, S J Utts, J Dev.   

Abstract

The secretin provocation test for gastrinoma is based on the premise that secretin decreases or has no effect on serum gastrin in normal and duodenal ulcer subjects while inducing a paradoxical rise in gastrinoma. We reexamined the serum gastrin response to pharmacologic amounts of secretin in normal volunteers (N = 17) and unoperated duodenal ulcer patients (N = 10). GIH secretin caused significant early gastrin rises from baseline in both groups (P less than 0.05). The gastrin response curves after secretin were not significantly different between normal and ulcer subjects. Similar gastrin rises were seen when synthetic secretin was administered to normal subjects (N = 6). In normal volunteers, intravenous bolus saline (N = 10) or amino acid (L-cysteine, N = 8) caused no change in serum gastrin from baseline. The gastrin response curves to GIH secretin and saline were significantly different (P less than 0.05). Our findings suggest that the gastrin rise in gastrinoma patients after secretin is an exaggeration of the normal response and not paradoxical.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3816477     DOI: 10.1007/bf01297046

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Calcium and secretin-stimulated gastrin release in the Zollinger-Ellison syndrome.

Authors:  B E Kolts; C A Herbst; J E McGuigan
Journal:  Ann Intern Med       Date:  1974-12       Impact factor: 25.391

2.  Secretin-stimulated serum gastrin levels in hyperparathyroid patients from families with multiple endocrine adenomatosis type I.

Authors:  C B Lamers; J T Buis; J van Tongeren
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

3.  Stimuli for heptadecapeptide gastrin release: a comparison of oral and intravenous arginiine-monochloride and oxo in normal, vagotomized and antrectomized patients.

Authors:  A I Vinik; W J Kalk; D M Dent; G Barbezat; B J Grant; S Bank
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

4.  Comparative study of the value of the calcium, secretin, and meal stimulated increase in serum gastrin to the diagnosis of the Zollinger-Ellison syndrome.

Authors:  C G Lamers; J H Van Tongeren
Journal:  Gut       Date:  1977-02       Impact factor: 23.059

5.  Calcium and secretin as provocative stimuli in the Zollinger-Ellison syndrome.

Authors:  A A Mihas; B I Hirschowitz; R G Gibson
Journal:  Digestion       Date:  1978       Impact factor: 3.216

6.  Serum gastrin response to secretin after vagotomy.

Authors:  M Feldman; J H Walsh; C T Richardson
Journal:  Dig Dis Sci       Date:  1980-12       Impact factor: 3.199

7.  Assessment of the secretin provocation test in the diagnosis of gastrinoma.

Authors:  J N Primrose; J G Ratcliffe; S N Joffe
Journal:  Br J Surg       Date:  1980-10       Impact factor: 6.939

8.  Secretin-induced gastrin response in the Zollinger-Ellison syndrome and chronic duodenal ulcer patients before and after cimetidine treatment.

Authors:  M Quatrini; G Basilisco; D Conte; M T Bardella; A Bozzani; P A Bianchi
Journal:  Am J Gastroenterol       Date:  1984-05       Impact factor: 10.864

9.  False-positive serum gastrin elevation during secretin stimulation due to Boots secretin.

Authors:  C E Brady; R C Johnson; J R Williams; K Boran
Journal:  J Clin Gastroenterol       Date:  1983-06       Impact factor: 3.062

10.  Pathomorphologic, biochemical, and diagnostic aspects of gastrinomas (Zollinger-Ellison syndrome).

Authors:  W Creutzfeldt; R Arnold; C Creutzfeldt; N S Track
Journal:  Hum Pathol       Date:  1975-01       Impact factor: 3.466

View more
  1 in total

1.  Secretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results.

Authors:  Scott H Long; Marc J Berna; Michelle Thill; Andrea Pace; Tapas K Pradhan; K Martin Hoffmann; Jose Serrano; Robert T Jensen
Journal:  J Clin Endocrinol Metab       Date:  2007-08-21       Impact factor: 5.958

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.